JP2011521974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521974A5 JP2011521974A5 JP2011511876A JP2011511876A JP2011521974A5 JP 2011521974 A5 JP2011521974 A5 JP 2011521974A5 JP 2011511876 A JP2011511876 A JP 2011511876A JP 2011511876 A JP2011511876 A JP 2011511876A JP 2011521974 A5 JP2011521974 A5 JP 2011521974A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- amorphous form
- drug delivery
- delivery device
- glass transition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003381 stabilizer Substances 0.000 claims description 11
- 230000009477 glass transition Effects 0.000 claims description 9
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 6
- 229960003086 naltrexone Drugs 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 3
- 229960002646 scopolamine Drugs 0.000 claims description 3
- 239000007962 solid dispersion Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 25
- 229940124597 therapeutic agent Drugs 0.000 claims 25
- 239000002270 dispersing agent Substances 0.000 claims 11
- 238000012377 drug delivery Methods 0.000 claims 11
- 230000000087 stabilizing effect Effects 0.000 claims 8
- 238000013271 transdermal drug delivery Methods 0.000 claims 5
- 239000000853 adhesive Substances 0.000 claims 4
- 230000001070 adhesive effect Effects 0.000 claims 4
- 239000012790 adhesive layer Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000003860 storage Methods 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 230000037384 skin absorption Effects 0.000 claims 2
- 231100000274 skin absorption Toxicity 0.000 claims 2
- 229920002367 Polyisobutene Polymers 0.000 claims 1
- 239000003522 acrylic cement Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000012456 homogeneous solution Substances 0.000 claims 1
- 238000010030 laminating Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 polysiloxane Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 238000004080 punching Methods 0.000 claims 1
- 229940100640 transdermal system Drugs 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5745508P | 2008-05-30 | 2008-05-30 | |
| US61/057,455 | 2008-05-30 | ||
| PCT/US2009/045739 WO2009158120A2 (en) | 2008-05-30 | 2009-05-29 | Stabilized transdermal drug delivery system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014232586A Division JP2015083569A (ja) | 2008-05-30 | 2014-11-17 | 安定化された経皮薬物送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521974A JP2011521974A (ja) | 2011-07-28 |
| JP2011521974A5 true JP2011521974A5 (enExample) | 2015-01-15 |
| JP5695562B2 JP5695562B2 (ja) | 2015-04-08 |
Family
ID=41380695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511876A Active JP5695562B2 (ja) | 2008-05-30 | 2009-05-29 | 安定化された経皮薬物送達システム |
| JP2014232586A Pending JP2015083569A (ja) | 2008-05-30 | 2014-11-17 | 安定化された経皮薬物送達システム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014232586A Pending JP2015083569A (ja) | 2008-05-30 | 2014-11-17 | 安定化された経皮薬物送達システム |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9226902B2 (enExample) |
| EP (1) | EP2299989B1 (enExample) |
| JP (2) | JP5695562B2 (enExample) |
| KR (1) | KR101590209B1 (enExample) |
| CN (1) | CN102099020B (enExample) |
| AU (2) | AU2009262871B2 (enExample) |
| BR (1) | BRPI0913214B1 (enExample) |
| CA (1) | CA2726136C (enExample) |
| MX (1) | MX2010012989A (enExample) |
| NZ (1) | NZ589542A (enExample) |
| WO (1) | WO2009158120A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2726136C (en) * | 2008-05-30 | 2016-11-01 | Mylan Laboratories, Inc. | Stabilized transdermal drug delivery system |
| KR101325104B1 (ko) * | 2009-09-16 | 2013-11-07 | 주식회사 삼양바이오팜 | 경피 투여 제형 및 그 제조 방법 |
| CN102665699A (zh) * | 2009-12-22 | 2012-09-12 | 优时比制药有限公司 | 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮 |
| WO2014028049A1 (en) * | 2012-08-15 | 2014-02-20 | Dow Corning Corporation | Multi - layer transdermal drug delivery system |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| JP2016135744A (ja) * | 2013-05-08 | 2016-07-28 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
| CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
| WO2015025767A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
| CN115444659A (zh) * | 2014-01-22 | 2022-12-09 | 4P治疗公司 | 滥用和误用制止透皮系统 |
| US11752110B2 (en) * | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| JP6573913B2 (ja) * | 2014-05-20 | 2019-09-11 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ロチゴチンを含む経皮送達システム |
| CA2948219C (en) | 2014-05-20 | 2023-04-04 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| EP3197275B1 (en) * | 2014-09-24 | 2021-11-24 | Pain Therapeutics, Inc. | 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal |
| US10010543B1 (en) | 2014-12-23 | 2018-07-03 | Barr Laboratories, Inc. | Transdermal dosage form |
| US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| KR102506333B1 (ko) | 2016-12-20 | 2023-03-06 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀을 함유하는 경피흡수 치료 시스템 |
| KR102241892B1 (ko) | 2017-01-25 | 2021-04-20 | 한국전자기술연구원 | 백스캐터 통신을 위한 데이터 부호화 방법 및 이를 위한 장치 |
| KR20180121352A (ko) | 2017-04-28 | 2018-11-07 | 닛토덴코 가부시키가이샤 | 경피 흡수형 제제 |
| EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| US20220117934A1 (en) * | 2019-02-15 | 2022-04-21 | Hisamitsu Pharmaceutical Co., Inc. | Rotigotine stabilization method |
| US20220160697A1 (en) * | 2019-03-19 | 2022-05-26 | Nobelpharma Co., Ltd. | Pharmaceutical composition having excellent drug absorption into the living body and excellent chemical stability |
| AU2020282832A1 (en) * | 2019-05-31 | 2022-02-03 | Kindeva Drug Delivery | Removable film-forming gel compositions featuring adhesion promoters |
| FI3854388T3 (fi) * | 2020-01-24 | 2023-11-27 | Luye Pharma Switzerland Ag | Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima |
| CA3193154A1 (en) * | 2020-08-31 | 2022-03-03 | Nobelpharma Co., Ltd. | Patch for alleviating or treating symptoms of neurodegenerative disease |
| CN112891324A (zh) * | 2021-01-19 | 2021-06-04 | 北京亚宝生物药业有限公司 | 一种透皮贴剂 |
| KR102363479B1 (ko) * | 2021-03-12 | 2022-02-15 | 환인제약 주식회사 | 로티고틴 함유 경피 흡수 제제 |
| EP4351536A1 (en) * | 2021-06-06 | 2024-04-17 | Starton Therapeutics, Inc. | Transdermal drug delivery systems for administration of a therapeutically effective amount of lenalidomide and other immunomodulatory agents |
| CN116270575A (zh) * | 2021-08-16 | 2023-06-23 | 乐明药业(苏州)有限公司 | 一种含有氟比洛芬的药物组合物与贴剂 |
| WO2024144130A1 (ko) * | 2022-12-26 | 2024-07-04 | 환인제약 주식회사 | 경피흡수용 제제 및 이의 제조 방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2920500A1 (de) | 1979-05-21 | 1980-11-27 | Boehringer Sohn Ingelheim | Pharmazeutische zubereitung in form eines polyacrylatfilmes |
| DE3204551A1 (de) | 1982-02-10 | 1983-08-18 | Boehringer Ingelheim KG, 6507 Ingelheim | Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films |
| JPS60169414A (ja) * | 1984-02-14 | 1985-09-02 | Taisho Pharmaceut Co Ltd | 経皮吸収剤 |
| US4797284A (en) | 1986-03-12 | 1989-01-10 | Merck & Co., Inc. | Transdermal drug delivery system |
| US4880633A (en) | 1986-03-12 | 1989-11-14 | Merck & Co., Inc. | Transdermal drug delivery system |
| US4832953A (en) * | 1987-08-13 | 1989-05-23 | Alza Corporation | Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| GB9021674D0 (en) | 1990-10-05 | 1990-11-21 | Ethical Pharma Ltd | Transdermal device |
| US5164190A (en) | 1990-12-11 | 1992-11-17 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
| IT1253265B (it) | 1991-11-25 | 1995-07-14 | Rotta Research Lab | Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo. |
| US5494680A (en) * | 1993-12-08 | 1996-02-27 | Minnesota Mining And Manufacturing Company | Transdermal delivery device |
| JP4102901B2 (ja) | 1994-09-14 | 2008-06-18 | スリーエム カンパニー | 経皮薬剤導入用マトリックス |
| US5662928A (en) | 1995-04-21 | 1997-09-02 | Ciba-Geigy Corporation | Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system |
| KR970009795A (ko) * | 1995-08-30 | 1997-03-27 | 이웅열 | 경피투여용 첩부제 조성물 |
| US5906830A (en) | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
| ES2162124T3 (es) | 1995-12-01 | 2001-12-16 | Alza Corp | Metodo mejorado para evitar la formacion de cristales en una dispersion de un liquido en una matriz. |
| US6238700B1 (en) | 1995-12-01 | 2001-05-29 | Alza Corporation | Method for preventing crystal formation in a dispersion of a liquid in a matrix |
| DE19548332A1 (de) * | 1995-12-22 | 1997-07-10 | Rotta Res Bv | Hormonpflaster |
| US6623763B2 (en) | 1996-01-08 | 2003-09-23 | Lts Lohmann Therape-System Ag | Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism |
| US5869089A (en) | 1996-03-21 | 1999-02-09 | China-America Technology Corp. (Ctc) | Manufacturing method of programmable transdermal therapeutic system |
| DE19629468A1 (de) * | 1996-07-11 | 1998-01-15 | Schering Ag | Transdermale therapeutische Systeme |
| US20040018241A1 (en) * | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| DE19906152B4 (de) * | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| DE10060550C1 (de) | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
| WO2003034961A1 (en) | 2001-10-23 | 2003-05-01 | Euro-Celtique, S.A. | Terazosin transdermal device and methods |
| US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| WO2005123046A1 (en) * | 2004-06-15 | 2005-12-29 | Amorepacific Corporation | Novel transdermal preparation and its producing method |
| DE102004062182B4 (de) * | 2004-12-20 | 2007-06-06 | Bayer Schering Pharma Ag | Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff |
| US20060188558A1 (en) * | 2005-02-18 | 2006-08-24 | Mylan Technologies, Inc. | Transdermal systems having control delivery system |
| JP5285279B2 (ja) | 2005-12-28 | 2013-09-11 | 久光製薬株式会社 | 経皮吸収型製剤 |
| US20080226698A1 (en) * | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
| ES2830073T3 (es) * | 2007-04-11 | 2021-06-02 | Omeros Corp | Composiciones y métodos para la profilaxis y el tratamiento de adicciones |
| CA2726136C (en) * | 2008-05-30 | 2016-11-01 | Mylan Laboratories, Inc. | Stabilized transdermal drug delivery system |
| BR112013021030A2 (pt) | 2011-02-17 | 2016-10-11 | Hoffmann La Roche | processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente |
-
2009
- 2009-05-29 CA CA2726136A patent/CA2726136C/en active Active
- 2009-05-29 BR BRPI0913214-7A patent/BRPI0913214B1/pt active IP Right Grant
- 2009-05-29 NZ NZ589542A patent/NZ589542A/xx not_active IP Right Cessation
- 2009-05-29 EP EP09770655.0A patent/EP2299989B1/en active Active
- 2009-05-29 US US12/475,390 patent/US9226902B2/en active Active
- 2009-05-29 WO PCT/US2009/045739 patent/WO2009158120A2/en not_active Ceased
- 2009-05-29 AU AU2009262871A patent/AU2009262871B2/en active Active
- 2009-05-29 MX MX2010012989A patent/MX2010012989A/es active IP Right Grant
- 2009-05-29 US US12/994,918 patent/US20110182949A1/en not_active Abandoned
- 2009-05-29 CN CN2009801289266A patent/CN102099020B/zh active Active
- 2009-05-29 JP JP2011511876A patent/JP5695562B2/ja active Active
- 2009-05-29 KR KR1020107029551A patent/KR101590209B1/ko active Active
-
2014
- 2014-11-17 JP JP2014232586A patent/JP2015083569A/ja active Pending
-
2016
- 2016-04-08 AU AU2016202212A patent/AU2016202212B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521974A5 (enExample) | ||
| JP4883220B2 (ja) | ロチゴチン含有組成物及びその使用並びにこの組成物を含む経皮貼付剤 | |
| CN1731995B (zh) | 用于经皮给药d2促进素碱的器具 | |
| CN104144684B (zh) | 含有多奈哌齐的经皮吸收制剂及其制备方法 | |
| JP5695562B2 (ja) | 安定化された経皮薬物送達システム | |
| CN102946873B (zh) | 经皮吸收制剂 | |
| JP6335790B2 (ja) | 自発的に結晶化する傾向が低い経皮治療システム | |
| JP2016504368A5 (enExample) | ||
| JPS6059207B2 (ja) | 複合製剤の製法 | |
| CN106659702A (zh) | 透皮递送体系 | |
| JP2006291180A5 (enExample) | ||
| JP2010248206A5 (enExample) | ||
| JP2010510260A5 (enExample) | ||
| JP2005528427A5 (enExample) | ||
| JP5665116B2 (ja) | 貼付剤および貼付製剤 | |
| JP2017515869A5 (enExample) | ||
| JP6948326B2 (ja) | テープ材用支持フィルム、テープ材、およびテープ材用支持フィルムの製造方法 | |
| EP2570122B1 (en) | Composition for Enhancing Transdermal Absorption of A Drug and Patch Preparation | |
| CN104661657B (zh) | 贴附剂或贴附制剂用的支承体以及使用该支承体的贴附剂和贴附制剂 | |
| JP6148861B2 (ja) | 貼付剤 | |
| JP5956660B2 (ja) | 塩基性反応酸化物を含む制御された活性物質流動を有する経皮治療システム | |
| CN112891324A (zh) | 一种透皮贴剂 | |
| JP2018537451A5 (enExample) | ||
| JP5930877B2 (ja) | 経皮吸収製剤 | |
| CN102935235B (zh) | 一种改性酪素载药缓释薄膜的制备方法 |